ReviewInternational journal of cancer2025
A promising frontier of circulating messenger RNA in liquid biopsy: From mechanisms to clinical applications.
Review in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Article
- Tumor-educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation.International journal of cancer · 2026Review
- THBS1: a biomarker for PCOS and its role in pathogenesis via the PI3K/AKT signaling pathway.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Circulating RNA as a Functional Component of Liquid Biopsy in Cancer: Concepts, Classification, and Clinical Applications.International journal of molecular sciences · 2026Review
- Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026Review
- Safety Assessment of Stem Cell-Based Therapies: Current Standards and Advancing Frameworks.Cells · 2025Review
- A promising frontier of circulating messenger RNA in liquid biopsy: From mechanisms to clinical applications.International journal of cancer · 2025Review
- Robust Cancer Biomarker Identification From Matched Transcriptomic Data Via Bootstrapped Regularized Conditional Logistic Regression.Cancer informatics · 2025Article
- Clinical Utility and Limitations of Circulating HPV DNA in Tonsillar Squamous Cell Carcinoma: A Narrative Review.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Liquid biopsy can revolutionize cancer patient management as repeated sampling allows real-time monitoring of disease progression and response to treatment. The circulating transcriptome represents a rich source of potential cancer biomarkers, including coding and non-coding RNAs. As techniques that have enabled us to analyze transcriptome profiling become ever more sophisticated, the great potential of extracellular messenger RNA (mRNA) and intracellular (cellular level) mRNA in liquid biopsy has gradually been realized. In this review, we aim to conclude the mRNA-based liquid biopsy in the tumorous context by illustrating the origins of mRNA markers and scientific findings, and summarizing the advantages of mRNAs over DNA-based liquid biopsy. Besides, we give a glimpse of the application of this strategy in clinical studies and analyze the gap between the bench and bedside. We speculate that mRNAs are a promising frontier of liquid biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.